Sigilon Therapeutics, Inc., a preclinical-stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes, and SIG-001 is in Phase I/II clinical trials to prevent bleeding episodes in patients with moderate to severe hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. The company was incorporated in 2015 and is based in Cambridge, Massachusetts. As of August 11, 2023, Sigilon Therapeutics, Inc. operates as a subsidiary of Eli Lilly and Company.